Skip to main content
Login
Contact
Subscribe
Search form
Search
The Decatur Daily Democrat
Home
Forms
Delivery Concerns
News
Sports
Obituaries
Classifieds
Place an Ad
Classified Display Ads
Photos
Videos
Games
Entertainment
Local Guide
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Xeris Pharmaceuticals Inc
(NQ:
XERS
)
5.370
USD
-0.370 (-6.45%)
Official Closing Price
Updated: 7:58 PM EST, Jan 15, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Xeris Pharmaceuticals Inc
< Previous
1
2
3
Next >
Xeris Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference
January 05, 2021
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug...
From
Business Wire News Releases
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 31, 2020
Xeris Pharmaceuticals, Inc. (NASDAQ: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug...
From
Business Wire News Releases
Xeris Pharmaceuticals Announces Distribution Agreement With Megapharm Ltd. to Commercialize Gvoke® in Israel and the Palestinian Authority
December 22, 2020
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible...
From
Business Wire News Releases
Thinking about buying stock in Nantkwest, Ampio Pharmaceuticals, Arbutus Biopharma, Xeris Pharmaceuticals, or iBio Inc?
December 11, 2020
InvestorsObserver issues critical PriceWatch Alerts for NK, AMPE, ABUS, XERS, and IBIO.
From
PR Newswire
Xeris Pharmaceuticals Receives Positive CHMP Opinion for Ogluo™, Its Ready-To-Use (RTU) Glucagon for Injection, for the Treatment of Severe Hypoglycaemia in Adults, Adolescents, and Children Aged 2 Ye
December 11, 2020
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectable and...
From
Business Wire News Releases
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 27, 2020
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug...
From
Business Wire News Releases
Xeris Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights
November 09, 2020
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectable and...
From
Business Wire News Releases
Xeris Pharmaceuticals to Announce Third Quarter 2020 Financial Results and Host Conference Call and Webcast on November 9, 2020
November 02, 2020
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible...
From
Business Wire News Releases
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 30, 2020
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug...
From
Business Wire News Releases
Xeris Pharmaceuticals Granted Fast Track Designation by the FDA for Its Novel Concentrated Diazepam Formulation (XP-0863) For Injection
October 20, 2020
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug...
From
Business Wire News Releases
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 02, 2020
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug...
From
Business Wire News Releases
Thinking about buying stock in Under Armour, Cassava Sciences, Norwegian Cruise Line, Xeris Pharmaceuticals, or Delta Air Lines?
September 23, 2020
InvestorsObserver issues critical PriceWatch Alerts for UAA, SAVA, NCLH, XERS, and DAL.
From
PR Newswire
Thinking about buying stock in Marinus Pharmaceuticals, Fiat Chrysler, Lithium Americas, Xeris Pharmaceuticals, or Nokia?
September 15, 2020
InvestorsObserver issues critical PriceWatch Alerts for MRNS, FCAU, LAC, XERS, and NOK.
From
PR Newswire
Thinking about buying stock in Rockwell Medical, Spotify, Xeris Pharmaceuticals, Blink Charging, or Nio Inc?
September 10, 2020
InvestorsObserver issues critical PriceWatch Alerts for RMTI, SPOT, XERS, BLNK, and NIO.
From
PR Newswire
Xeris Pharmaceuticals to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 08, 2020
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug...
From
Business Wire News Releases
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
August 28, 2020
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug...
From
Business Wire News Releases
Xeris Pharmaceuticals Appoints John Shannon President and Chief Operating Officer
August 20, 2020
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectable and...
From
Business Wire News Releases
Xeris Pharmaceuticals Reports Second Quarter 2020 Financial Results and Corporate Highlights
August 10, 2020
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use (RTU) injectable and...
From
Business Wire News Releases
Xeris Pharmaceuticals to Announce Second Quarter 2020 Financial Results and Host Conference Call and Webcast on August 10, 2020
August 03, 2020
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible...
From
Business Wire News Releases
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
July 31, 2020
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug...
From
Business Wire News Releases
Xeris Pharmaceuticals Announces Additional Data From a Phase 1b Comparative Study of Its Novel Concentrated Diazepam Formulation (XP-0863) and an Expedited Clinical Path Forward
July 30, 2020
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug...
From
Business Wire News Releases
Xeris Pharmaceuticals Announces Full Exercise of Underwriters’ Options to Purchase Additional Shares and Additional Notes
July 15, 2020
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug...
From
Business Wire News Releases
Thinking about buying stock in Southwest Airlines, Xeris Pharmaceuticals, Electrameccanica Vehicles, Delta Air Lines, or Shopify?
July 02, 2020
InvestorsObserver issues critical PriceWatch Alerts for LUV, XERS, SOLO, DAL, and SHOP.
From
PR Newswire
Thinking about buying stock in T2 Biosystems, Ameresco Inc, Xeris Pharmaceuticals, Blink Charging, or Kitov Pharma?
July 01, 2020
InvestorsObserver issues critical PriceWatch Alerts for TTOO, AMRC, XERS, BLNK, and KTOV.
From
PR Newswire
Xeris Pharmaceuticals Announces Gvoke HypoPen™ – the First Autoinjector for Severe Hypoglycemia – Now Available
July 01, 2020
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use injectable and infusible...
From
Business Wire News Releases
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
June 26, 2020
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug...
From
Business Wire News Releases
Xeris Pharmaceuticals Announces Pricing of Public Offerings of $20 Million of Common Stock and $75 Million of 5.00% Convertible Senior Notes Due 2025
June 25, 2020
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug...
From
Business Wire News Releases
Xeris Pharmaceuticals Announces Proposed Public Offerings of $20 Million of Common Stock and $60 Million of Convertible Senior Notes
June 24, 2020
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug...
From
Business Wire News Releases
Xeris Pharmaceuticals Announces Positive Topline Results from the Phase 2 Comparative Study of a Novel Pramlintide-insulin Co-formulation (XP-3924) in Adults with Type 1 Diabetes Mellitus
June 18, 2020
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug...
From
Business Wire News Releases
Faruqi & Faruqi, LLP is Investigating Xeris Pharmaceuticals, Inc. (XERS) on Behalf of its Shareholders
June 15, 2020
From
GlobeNewswire News Releases
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
